-+ 0.00%
-+ 0.00%
-+ 0.00%

Outlook Therapeutics names Kevin Lundquist CFO, replacing Lawrence Kenyon

PUBT·08/27/2026 20:07:20
Listen to the news
Outlook Therapeutics names Kevin Lundquist CFO, replacing Lawrence Kenyon
  • Outlook Therapeutics named Kevin Lundquist chief financial officer, effective Sept. 1, 2026.
  • Lundquist previously served as CFO of CapsoVision, overseeing finance and operations through its 2025 IPO process.
  • Earlier roles include CFO of Abzena Biologics, VP of finance at Revance Therapeutics, finance leadership at Genentech/Roche.
  • Lawrence Kenyon will step down as CFO on Sept. 1, 2026, staying as a non-executive employee through Sept. 30, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outlook Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608271605PRIMZONEFULLFEED9817345) on August 27, 2026, and is solely responsible for the information contained therein.